Navigation Links
Preclinical Studies Show Promise for Novel Antibody Therapy to Treat Acute Myeloid Leukemia (AML)
Date:12/10/2007

eated AML stem cells. The overall survival of treated engrafted mice was significantly improved with the median survival of control group 11.5 weeks versus 24 weeks for the antibody-treated group.

Secondly, 7G3 was administered to mice with established AML. Administration of the antibody to these mice reduced AML dissemination around the body of the mice. The ability of leukemic stem cells from mice treated in this way to reestablish leukemia as secondary transplants into other animals was markedly reduced.

In contrast, exposure to 7G3 had little effect on normal human bone marrow stem cells.

"These results show that 7G3 is able to target LSC's to prevent them from moving around and proliferating in the mice, while at the same time having little effect on normal blood cells," said Dr Lock at the ASH meeting today.

"This is a very exciting finding because it is one of the first drugs that has been designed to specifically target the LSC, rather than simply attacking the cancer cells proliferating in the blood and bone marrow. Hopefully this means that it can fight leukemia without many of the side effects of current drugs. It opens up an exciting new option for the treatment of AML," he said.

CSL wishes to acknowledge the contribution of the University Health Network in Toronto, Canada, The Institute of Medical and Veterinary Science/Hanson Institute for Cancer Research in South Australia, Children's Cancer Institute Australia for Medical Research in Sydney, Australia and the Queensland Institute for Medical Research, Australia, its key collaborators in this important project.

For further information please contact:

Associate Professor Richard Lock

Head, Leukaemia Biology Program

Children's Cancer Institute Australia for Medical Research

Phone: +61 414 769 194

Dr. Darryl Maher

Medical Director

CSL Bioplasma

Phone: +61 412 346 987

Media Contact

Sheila A. Burk
'/>"/>

SOURCE CSL Limited
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
3. Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
6. Isis Reports Preclinical Data Supporting Liver Safety of ISIS 301012
7. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
8. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
9. Tezampanel, TorreyPines Therapeutics Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
10. Telik Announces Presentation of Preclinical Data on Dual Inhibitors of Aurora Kinases and VEGFR2
11. CorNova Preclinical Results of Valecor Platinum(TM) Coronary Stent Studies Presented at TCT 2007 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... DALLAS , July 3, 2015 ... report "Cardiac Monitoring & Cardiac Rhythm Management Market ... Output Monitoring, Defibrillator, Implantable Cardioverter Defibrillator, Dual Chamber ... published by MarketsandMarkets, the global Cardiac Monitoring (CM) ... poised to reach $26,646.5 Million by 2020 from ...
(Date:7/3/2015)... 2015 A global continuing medical ... and thyroid disorders in Latin America ... conference dedicated to these diseases.      (Logo: ... Manage Hypertension Online and Manage Thyroid ... EXCEMED - combine the world,s top expertise with ...
(Date:7/3/2015)... , July 3, 2015  Obsidian HDS, the ... an online service for the management of data on ... today that PharmaShine now includes the 2014 Open Payments ... Medicare Services on June 30. The data disclosed on ... transactions between industry and providers totaling $6.49 billion and ...
Breaking Medicine Technology:Cardiac Monitoring (CM) and Cardiac Rhythm Management (CRM) Devices Market Worth $26,646.5 Million by 2020 2Cardiac Monitoring (CM) and Cardiac Rhythm Management (CRM) Devices Market Worth $26,646.5 Million by 2020 3Cardiac Monitoring (CM) and Cardiac Rhythm Management (CRM) Devices Market Worth $26,646.5 Million by 2020 4Combating Three Major Chronic Diseases in Latin America With Medical Education 2New Open Payments (Sunshine Act) Data Now Searchable on PharmaShine 2
... Phase 3 Once Weekly Investigational Diabetes Therapy Also Improved ... from Exenatide Taken Twice a Day, SAN FRANCISCO, ... Eli Lilly and Company (NYSE: LLY ), and ... a 52-week open-label clinical,study that showed the durable efficacy ...
... VIEW, Calif., June 9 Alexza,Pharmaceuticals, Inc. (Nasdaq: ... Phase 2a proof-of-concept clinical trial with AZ-002 (Staccato(R),alprazolam) ... not meet its two,primary endpoints, which were the ... panic attack and the effect of AZ-002 on ...
Cached Medicine Technology:After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 2After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 3After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 4After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 5After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 6After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 7After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 8After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 9Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder 2Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder 3Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder 4
(Date:7/2/2015)... ... ... LLC. is pleased to announce the opening of its newest location in Dallas, Texas. The ... frozen yogurt chain was listed as #22 on the Inc. 500 list of fastest growing ... Lake, is located at:, 3701 W. Northwest Highway, STE 430, Dallas, TX 75220 , “We ...
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... ... the parking structure retrofit project at the University of Minnesota, they knew it ... that it would also be an award-winning choice: the total energy savings after ...
(Date:7/2/2015)... ... July 02, 2015 , ... “ LIFX ” was ... and coolest technology products available to consumers. Amanda Forstrom, a technology expert and special ... are the most versatile smart light bulbs on the market. , According to the ...
(Date:7/2/2015)... ... July 02, 2015 , ... Six months ahead of his 80th birthday, Don ... awareness and money for the Pulmonary Hypertension Association (PHA). Stevenson began the walk ... Washington, D.C. by mid-September. He left Glasgow, Mont. yesterday morning and is making his ...
(Date:7/2/2015)... (PRWEB) , ... July 02, ... ... wound therapy (NPWT) - pipeline review 2015” provides comprehensive information on the ... development. Complete report on negative pressure wound therapy (NPWT) with 22 market ...
Breaking Medicine News(10 mins):Health News:sweetFrog Opens 18th Location in the Lone Star State 2Health News:Kenall’s TekDek™ Helps University Achieve Award-Winning Energy Savings in Parking Structure Lighting Retrofit 2Health News:The Most Versatile Smart Light Bulbs were featured on NewsWatch Television 2Health News:79-Year-old ‘Pacing Parson’ Passes 1,000-Mile Mark in Cross-Country Walk for Pulmonary Hypertension Association 2Health News:79-Year-old ‘Pacing Parson’ Passes 1,000-Mile Mark in Cross-Country Walk for Pulmonary Hypertension Association 3Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 4
... studies are now attempting to reveal the factors that play a ... Spanish researchers shows that a physically active lifestyle during adolescence can ... someone to becoming overweight or obese. Among the genes ... of the genes responsible for the accumulation of fat in humans. ...
... ... for a discreet and laidback escape, in total peace. , , ... (PRWEB) May 1, 2010 -- What is Euterpini? , , ,Eight typical local villas, ... on the sea on the western side of the island of Pantelleria , and named after ...
... ... hope for chronic sinusitis patients. The NasoNeb™ Nasal Nebulizer may be used ... and corticosteroids. , ... Camarillo, CA (PRWEB) May 4, 2010 -- Chronic sinusitis patients have new hope ...
... identified that a key protein called PEA-15 stops T-cell proliferation ... T-cell proliferation is essential in preventing certain blood cancers and ... response to infection. Findings of the study are reported ... , a publication of The Federation of American Societies for ...
... researchers at Columbia University,s Mailman School of Public Health ... genes, altering their functions and leading to the development ... suggest a new biological model of PTSD in which ... a person,s stress response and leads to the disorder," ...
... Researchers at LSU Health Sciences Center New Orleans ... there is a major difference in the hemoglobin ... African-American and Caucasian children with diabetes. HbA1c is the ... decisions. African-American children test significantly higher than Caucasians who ...
Cached Medicine News:Health News:Physical activity reduces the effect of the obesity gene in adolescents 2Health News:New Nasal Drug Delivery Device for Chronic Sinusitis Patients Now Available from ASL Pharmacy 2Health News:New Nasal Drug Delivery Device for Chronic Sinusitis Patients Now Available from ASL Pharmacy 3Health News:New Nasal Drug Delivery Device for Chronic Sinusitis Patients Now Available from ASL Pharmacy 4Health News:Study finds key protein controls T-cell proliferation 2Health News:Trauma-induced changes to genes may lead to PTSD 2Health News:Definitive diabetes indicator deceptively high in African-American children 2
ISI DuraHand is the reusable, easy to sterilize surgical hand immobilizer....
... DataPro is a smart, sophisticated and compact medium ... cost effective chemistry analyser in its class! It ... do 230 tests per hour. The DataPro runs ... a normal biochemistry laboratory and runs a wide ...
MagaCell-Streptavidin is a streptavidin coupled to magnetizable cellulose/iron oxide particles...
BioVintages Biotin-Trapper™ Streptavidin Magnetic Beads (1 mm - 2 mm) are designed for single-step capture of biotinylated molecules such as DNA, RNA or protein from cell lysates or hybridizatio...
Medicine Products: